

66 (1) (2)

45

31

21

14

6.5

Fig. 1A

66 (1) (2) (3) (4)

45

31

21

14

6.5

Fig. 1B









Fig. 1C



**Fig. 2A**



**Fig. 2B**



Saliva IgA anti-holotoxin (specific / total  $\times 100$ )

Vaginal IgA anti-holotoxin (specific / total  $\times 100$ )




Fig. 4A

Immunogen/ Group

- SBR-CTA2/B
- SBR-LT-IIaA2/B




Fig. 4B

Immunogen/Group

- SBR-CTA2/B
- SBR-LT-IIaA2/B

Immunogen/Group

▨ SBR-CTA2/B

▨ SBR-LT-IIaA2/B




Fig. 4C

Immunogen/Group

▨ SBR-CTA2/B

▨ SBR-LT-IIaA2/B







Fig. 4D




**Fig. 5A**




**Fig. 5B**




**Fig. 6A**




**Fig. 6B**




**Fig. 6C**



**Fig. 6D**



**Fig. 6E**



**Fig. 7**

Ab Treatment:




Fig. 8A

Ab Treatment:




Fig. 8B

Ab Treatment:




Fig. 8C

Ab Treatment:




Fig. 8D